Under the trend of innovation, the number of clinical trials in China has soared

"Pharmaceutical network industry dynamics" whether it is "the combination of imitation" or independent innovation, in order to survive in the future pharmaceutical environment, pharmaceutical companies have to bring some "new" research and development pipeline.
years, the state has been introducing policies to encourage drug innovation, innovation and development has been the trend.
the same time with the volume of procurement of the national expansion, ordinary generic drugs into the era of micro-profit.
high-tech barriers have become the development direction of pharmaceutical enterprises.
Innovating, the number of clinical trials in China has soared (Photo: Pharmaceutical Network) In this trend, with the reform of China's new drug review and approval and the accelerated global market of new drugs, participation in global drug clinical trials has increasingly become an important work of Chinese pharmaceutical companies.
Fact, china as an important position of global pharmaceutical innovation, since 2016, China's policy environment, capital environment, talent environment, market environment are for China's pharmaceutical industry innovation to lay a grand prelude and music.
and the number of clinical trials as an important indicator of the pharmaceutical industry's innovation potential, its magnitude largely reflects the achievements and influence of China's pharmaceutical research and development innovation reform in the past few years.
, the number of clinical trials in China has grown rapidly since 2016, according to data.
double-digit growth rate in the number of clinical trials conducted in China from 2016 to 2019.
year-on-year U.S., the number of clinical trials grew by 10.17 percent in 2016-2017, with single-digit growth for the rest of the year.
note that in the first half of 2020, the number of clinical trials conducted in China has surpassed that of the United States for the first time.
continue this trend, China will be the world's leading country in clinical trials by 2020.
addition to this, it can be found from the data that it may be affected by the 2020 outbreak.
the first half of 2020, the number of clinical trials on respiratory diseases and infectious diseases in China was higher, with the number of clinical trials targeting tumors coming in third place, followed by neurological diseases and gastrointestinal diseases.
it is worth noting that in the first half of 2020, more clinical trials will be conducted in China than in the United States.
From the above domestic clinical trials continue to grow, it can be seen that in recent years, under the influence of the "4 plus 7" volume procurement, medical insurance control fees, two-vote system and other policies, a number of enterprises product sales, prices fell sharply, sales and profit pressure, enterprises have begun to measure their own development strategy, accelerate the transition to innovation.
the innovation intensity and speed caused by enterprise scale, development strategy and other factors are different, but innovation is the general trend has become a consensus.
fact, from the recent announcement of a large number of enterprises, it is clear that in the second half of the year, there are still many pharmaceutical companies are accelerating Mercedes-Benz in the direction of innovation.
e.g., on September 8th, the CD3/CD20 dual-specific antibody REG1979 injection submitted by Redding Pharmaceuticals/Regeneratives was approved clinically in China for patients with B-cell non-Hodgkin's lymphoma (B-NHL) who have relapsed or are difficult to treat after previous systemic treatment.
September 15, Angjin/Baiji Shenzhou Class 1 new drug AMG 199 was approved clinically in China for the treatment of MCC17-positive gastric cancer or gastroesophageal junction (G/GEJ) cancer.
generally enough, the future of Chinese medicine lies in innovation, which is the force of China's pharmaceutical industry to participate in international competition, and also an important force in the transformation and upgrading of China's pharmaceutical industry to strengthen the competitiveness of the industry.
with the success of clinical trials in the future, the domestic market for innovative drugs may usher in a major outbreak.